Nevro Corp. (NVRO): Price and Financial Metrics
NVRO Price/Volume Stats
| Current price | $27.52 | 52-week high | $53.34 |
| Prev. close | $28.27 | 52-week low | $25.82 |
| Day low | $27.32 | Volume | 267,200 |
| Day high | $28.05 | Avg. volume | 584,217 |
| 50-day MA | $30.98 | Dividend yield | N/A |
| 200-day MA | $37.92 | Market Cap | 985.68M |
NVRO Stock Price Chart Interactive Chart >
NVRO POWR Grades
- NVRO scores best on the Value dimension, with a Value rank ahead of 86.98% of US stocks.
- NVRO's strongest trending metric is Growth; it's been moving down over the last 179 days.
- NVRO's current lowest rank is in the Sentiment metric (where it is better than 14.08% of US stocks).
NVRO Stock Summary
- With a price/earnings ratio of 421.01, NEVRO CORP P/E ratio is greater than that of about 98.74% of stocks in our set with positive earnings.
- The price/operating cash flow metric for NEVRO CORP is higher than 90.27% of stocks in our set with a positive cash flow.
- Of note is the ratio of NEVRO CORP's sales and general administrative expense to its total operating expenses; 99.35% of US stocks have a lower such ratio.
- Stocks with similar financial metrics, market capitalization, and price volatility to NEVRO CORP are SSTI, VZIO, NRDS, CERT, and NABL.
- Visit NVRO's SEC page to see the company's official filings. To visit the company's web site, go to www.nevro.com.
NVRO Valuation Summary
- In comparison to the median Healthcare stock, NVRO's EV/EBIT ratio is 803.33% higher, now standing at 108.4.
- NVRO's price/sales ratio has moved down 19.3 over the prior 104 months.
Below are key valuation metrics over time for NVRO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NVRO | 2023-05-23 | 2.3 | 3.2 | 421.6 | 108.4 |
| NVRO | 2023-05-22 | 2.4 | 3.3 | 426.6 | 109.5 |
| NVRO | 2023-05-19 | 2.3 | 3.2 | 421.3 | 108.3 |
| NVRO | 2023-05-18 | 2.4 | 3.2 | 425.6 | 109.3 |
| NVRO | 2023-05-17 | 2.4 | 3.3 | 433.2 | 111.0 |
| NVRO | 2023-05-16 | 2.4 | 3.3 | 429.7 | 110.2 |
NVRO Growth Metrics
- Its 2 year revenue growth rate is now at -2.39%.
- The 4 year revenue growth rate now stands at 54.95%.
- Its 2 year cash and equivalents growth rate is now at -63.51%.
The table below shows NVRO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 395.281 | 22.939 | -7.941 |
| 2022-06-30 | 388.02 | -71.773 | -139.524 |
| 2022-03-31 | 386.137 | -63.428 | -136.124 |
| 2021-12-31 | 386.905 | -41.881 | -131.36 |
| 2021-09-30 | 393.876 | -14.863 | -108.355 |
| 2021-06-30 | 409.131 | 11.835 | -68.265 |
NVRO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NVRO has a Quality Grade of C, ranking ahead of 65.95% of graded US stocks.
- NVRO's asset turnover comes in at 0.556 -- ranking 79th of 186 Medical Equipment stocks.
- CSII, KRMD, and BIOL are the stocks whose asset turnover ratios are most correlated with NVRO.
The table below shows NVRO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.556 | 0.700 | -0.058 |
| 2021-03-31 | 0.469 | 0.693 | -0.084 |
| 2020-12-31 | 0.521 | 0.690 | -0.093 |
| 2020-09-30 | 0.596 | 0.690 | -0.124 |
| 2020-06-30 | 0.673 | 0.689 | -0.160 |
| 2020-03-31 | 0.867 | 0.697 | -0.146 |
Nevro Corp. (NVRO) Company Bio
Nevro Corporation develops and commercializes a neuromodulation platform for the treatment of chronic pain. The company was founded in 2006 and is founded in Menlo Park, California.
Latest NVRO News From Around the Web
Below are the latest news stories about NEVRO CORP that investors may wish to consider to help them evaluate NVRO as an investment opportunity.
Nevro Names New Chief Commercial OfficerNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Greg Siller has been appointed Senior Vice President and Chief Commercial Officer of Nevro, effective June 19, 2023. Mr. Siller replaces Niamh Pellegrini, who will be leaving the organization effective June 9. The company also announced that in conjunction with this appointment, it is updating its revenue guidance for the seco |
Why Is OPKO Health (OPK) Down 17.2% Since Last Earnings Report?OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Nevro to Present at Jefferies Healthcare ConferenceNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Kevin Thornal, Nevro's CEO and President, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 10:30 am Eastern Time at the Marriott Marquis Hotel in New York, NY. |
Nevro Corp.'s (NYSE:NVRO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatioNevro Corp. ( NYSE:NVRO ) shareholders that were waiting for something to happen have been dealt a blow with a 26... |
Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company ManualNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced on April 24, 2023, the Board of Director of Nevro granted restricted stock unit awards covering an aggregate of 135,623 shares of its common stock (the RSU Award) and performance unit awards covering 135,623 shares of its common stock (the PSU Award and together, the Awards) to Kevin Thornal, who joined Nevro as its Chief Executive |
NVRO Price Returns
| 1-mo | 1.62% |
| 3-mo | -12.16% |
| 6-mo | -35.99% |
| 1-year | -41.93% |
| 3-year | -78.32% |
| 5-year | -63.76% |
| YTD | -30.51% |
| 2022 | -51.15% |
| 2021 | -53.17% |
| 2020 | 47.27% |
| 2019 | 202.24% |
| 2018 | -43.67% |
Continue Researching NVRO
Here are a few links from around the web to help you further your research on Nevro Corp's stock as an investment opportunity:Nevro Corp (NVRO) Stock Price | Nasdaq
Nevro Corp (NVRO) Stock Quote, History and News - Yahoo Finance
Nevro Corp (NVRO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...